Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08 ... their holdings of TXG. RA Capital Management L.P. purchased a new position ...

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report ... missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and ...

By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 55.6. A bullish investor could look at TXG's 27.9 RSI reading today as a sign that the recent heavy selling is in the process of ...

10x Genomics (TXG) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares ... the year versus the S&P 500's gain of 3.2%.

Thank you for standing by. My name is [Prilla] and I will be your conference operator today. At this time, I would like to welcome everyone to the 10x Genomics Fourth Quarter and Full Year 2024 ...